Note 19 - Segment and Geographic Information

12 Months Ended

May 31, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

19.  SEGMENT AND GEOGRAPHIC INFORMATION

Through February 2013, the Company was organized by geographic area and reported three operating segments: United States (“U.S.”), Europe and Other. In March 2013, after the acquisition of the LIFECODES business, the Company reorganized its operating structure, and reevaluated its reportable operating segments accordingly. The Company determines operating segments in accordance with its internal operating structure, which is now organized based upon product groups. Each segment is separately managed and is evaluated primarily upon operating results. As of May 31, 2013, the Company has two operating segments, the Transfusion segment and the Transplant & Molecular segment, which have been aggregated into one reportable segment. The financial information provided below has been recast to reflect the Company’s new segment structure for each period presented.

The Company manufactures and markets a complete line of diagnostics products and automated systems used primarily by hospitals, donor centers and reference laboratories in a number of tests performed to detect and identify certain properties of human blood and human tissue to ensure the most compatible match between patient and donor. These tests are performed for the purpose of blood transfusion, pre-transplant human leukocyte antigen (HLA) typing and screening processes as well as post-transplant patient monitoring to aid in the identification of graft rejection.

The Company operates in various geographies. These geographic markets are comprised of the United States, Europe, Canada and other international markets. Major international markets include Mexico, and the Asia Pacific region. These products are marketed globally, both directly to the end user and through established distributors.

Accounting policies for segments are the same as those described in the summary of significant accounting policies.

The following segment data is presented for the twelve months ended May 31, 2013, May 31, 2012 (separated into Predecessor and Successor periods), and May 31, 2011 as follows (in thousands):

			Successor		Predecessor
			August 20, 2011		June 1, 2011
	Year Ended		through		through		Year Ended
	May 31, 2013		May 31, 2012		August 19, 2011		May 31, 2011
Net sales by product group:
Transfusion	$	330,931		257,046		73,632		327,304
Transplant & Molecular		16,857		4,768		1,278		5,787
Total	$	347,788		261,814		74,910		333,091

Following is a summary of enterprise-wide information (in thousands):

			Successor		Predecessor
			August 20, 2011		June 1, 2011
	Year Ended		through		through		Year Ended
	May 31, 2013		May 31, 2012		August 19, 2011		May 31, 2011
Net sales to customers by geography are as follows:
United States	$	229,944		173,918		50,988		227,263
Europe (A)		63,643		49,486		14,180		61,743
Canada		19,985		14,349		3,907		16,447
Other		34,216		24,061		5,835		27,638
Total	$	347,788		261,814		74,910		333,091

	As of May 31
	2013		2012
Long-lived assets (excluding goodwill and intangibles) by geography:
United States	$	57,184		45,509
Europe (B)		13,399		14,394
Canada		4,511		4,004
Other (C)		1,287		755
Total	$	76,381		64,662

	As of May 31
	2013		2012
Concentration of net assets by geography:
United States	$	485,968		489,950
Europe		114,740		104,145
Canada		32,910		30,790
Other (C)		11,088		12,493
Total	$	644,706		637,378

(A) - Net sales to any individual country within Europe were not material to the Company's consolidated net sales.

(B) - Long-lived assets located in any individual country within Europe were not material to the Company's consolidated long-lived assets.

(C ) - Primarily Japan and India

Sales to an individual customer did not exceed more than 10% of our annual net sales during any of the year ended May 31, 2013, the Successor and Predecessor fiscal 2012 periods or the year ended May 31, 2011.